Form 4: Daxor Corp Director Edward Feuer Granted Stock Options Contingent on SEC Approval

Director Edward Feuer of Daxor Corp reports the acquisition of stock options, contingent on SEC approval of an amendment to the company's incentive compensation plan.

Summary

• Edward Feuer, a director of Daxor Corp, filed a Form 4 indicating a transaction involving derivative securities.
• On July 15, 2024, Feuer was granted stock options to purchase 2,500 shares of Daxor Corp common stock at an exercise price of $9.20.
• The grant is contingent upon the SEC approving an amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• The stock options vest in three installments: 833 on July 15, 2024, 833 on July 15, 2025, and 834 on July 15, 2026.
• Feuer directly owns 2,500 derivative securities following the reported transaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, with a slight positive due to aligning director interests with shareholders, but tempered by the contingency on SEC approval.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The stock option grant is contingent on SEC approval of the amendment to the Daxor Corporation 2020 Incentive Compensation Plan; failure to obtain this approval would nullify the grant.

Future Outlook

The future outlook depends on the SEC's approval of the amendment to the Daxor Corporation 2020 Incentive Compensation Plan, which is necessary for the stock options to vest.

Industry Context

Stock option grants are a common form of executive compensation in the corporate world, used to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across various industries.
• The vesting schedule of three years is also a common practice to ensure long-term commitment.
• The specific terms of the grant (number of options, exercise price, vesting schedule) would need to be compared to similar companies in the diagnostics or medical device industry to assess its competitiveness.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see it as a positive sign of the company's commitment to incentivizing its leadership.

Next Steps

• SEC approval of the amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• Vesting of the stock options on the specified dates.

Key Dates